Open Access. Powered by Scholars. Published by Universities.®
Pharmacy and Pharmaceutical Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Pharmacy and Pharmaceutical Sciences
Lobeline Compounds As A Treatment For Psychostimulant Abuse And Withdrawal, And For Eating Disorders, Peter A. Crooks, Linda P. Dwoskin
Lobeline Compounds As A Treatment For Psychostimulant Abuse And Withdrawal, And For Eating Disorders, Peter A. Crooks, Linda P. Dwoskin
Pharmaceutical Sciences Faculty Patents
Methods are disclosed that suggest the use of lobeline and analogs thereof in treating individuals for drug dependence and withdrawal and for eating disorders.
Chimeric Isoprenoid Synthases And Uses Thereof, Joseph Chappell, Kyoungwhan Back
Chimeric Isoprenoid Synthases And Uses Thereof, Joseph Chappell, Kyoungwhan Back
Pharmaceutical Sciences Faculty Patents
Disclosed is a chimeric isoprenoid synthase polypeptide including a first domain from a first isoprenoid synthase joined to a second domain from a second, heterologous isoprenoid synthase, whereby the chimeric isoprenoid synthase is capable of catalyzing the production of isoprenoid reaction products that are not produced in the absence of the second domain of the second, heterologous isoprenoid synthase. Also disclosed is a chimeric isoprenoid synthase polypeptide including an assymetrically positioned homologous domain, whereby the chimeric isoprenoid synthase is capable of catalyzing the production of isoprenoid reaction products that are not produced when the domain is positioned at its naturally-occurring …
Nornicotine Enantiomers For Use As A Treatment For Dopamine Related Conditions And Disease States, Peter A. Crooks, Linda Phyliss Dwoskin, Michael Thomas Bardo
Nornicotine Enantiomers For Use As A Treatment For Dopamine Related Conditions And Disease States, Peter A. Crooks, Linda Phyliss Dwoskin, Michael Thomas Bardo
Pharmaceutical Sciences Faculty Patents
Optically active nornicotine compounds as a treatment for dopamine-related conditions and disease states. Such disease states include the treatment of myasthenia gravis, Parkinson's disease, Alzheimer's disease, schizophrenia, eating disorders, ulcers, drug addiction and as a substitute for psycho-stimulant self-administration.
N-Chloro-N-Methyl Glucamine And N-Chloro-N-Methyl Glucamine Esters As Novel Safe Agents For Water Disinfetion, Anwar A. Hussain, Bassam Tashtoush, Lewis W. Dittert
N-Chloro-N-Methyl Glucamine And N-Chloro-N-Methyl Glucamine Esters As Novel Safe Agents For Water Disinfetion, Anwar A. Hussain, Bassam Tashtoush, Lewis W. Dittert
Pharmaceutical Sciences Faculty Patents
The present invention relates to N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters, and their use as agents for water disinfection and as mild oxidizing agents for the radiolabeling of oxidation-sensitive biomolecules.